Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

224.53
+0.12000.05%
Post-market: 224.530.00000.00%19:41 EDT
Volume:1.77M
Turnover:395.25M
Market Cap:29.96B
PE:39.96
High:225.90
Open:222.03
Low:218.39
Close:224.41
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:1.20
T/O Rate:1.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:22.12
PE(LYR):96.36

Loading ...

Tenaya Therapeutics Q1 net loss widens, misses analyst expectations

Reuters
·
May 07

Vir Biotechnology Q1 net loss widens

Reuters
·
May 07

Alnylam Pharmaceuticals Price Target Maintained With a $510.00/Share by HC Wainwright & Co.

Dow Jones
·
May 05

Alnylam presents new vutrisiran analyses at Heart Failure congress

Reuters
·
May 04

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in Attr-Cm

THOMSON REUTERS
·
May 04

Alnylam price target raised to $370 from $360 at Morgan Stanley

TIPRANKS
·
May 01

Alnylam price target lowered to $447 from $448 at Bernstein

TIPRANKS
·
May 01

Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
May 01

RBC Trims Price Target on Alnylam Pharmaceuticals to $445 From $450, Keeps Outperform Rating

MT Newswires Live
·
May 01

Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Alnylam Pharma (ALNY) and Avantor (AVTR)

TIPRANKS
·
May 01

Alnylam Pharma (ALNY) Gets a Buy from Bernstein

TIPRANKS
·
May 01

Raymond James Reaffirms Their Hold Rating on Alnylam Pharma (ALNY)

TIPRANKS
·
May 01

Outside Review Warns Alnylam Pharmaceuticals Stock Carries High Risk of Significant Losses

TIPRANKS
·
May 01

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Alignment Healthcare (ALHC)

TIPRANKS
·
May 01

Alnylam reports Q1 EPS $1.99, consensus $1.47

TIPRANKS
·
May 01

Sector Update: Health Care Stocks Rise Premarket Thursday

MT Newswires Live
·
Apr 30

Alnylam Q1 FY26 GAAP net income swings to USD 205.99 million; revenue rises 96% to USD 1.17 billion

Reuters
·
Apr 30

Alnylam Pharmaceuticals Shares up 7.9% Premarket After Q1 Profit Beat

THOMSON REUTERS
·
Apr 30

GUIDANCE: (ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.90B - $5.30B

MT Newswires Live
·
Apr 30

Alnylam Q1 net product revenue jumps 121%, adjusted EPS beats estimates

Reuters
·
Apr 30